Oruka Therapeutics (ORKA) SVP Arjun Agarwal Sells 9,459 Shares

Arjun Agarwal, who serves as the Senior Vice President of Finance at Oruka Therapeutics, Inc. (ORKA), recently increased his stake in the company. On June 12, 2026, Agarwal purchased 9,459 shares of the Nasdaq-listed biotechnology firm. This transaction occurred just days before a series of sales by other company executives, including Agarwal himself, who sold a much smaller block of 395 shares on June 15 as part of a pre-arranged trading plan.

Insider Buying and Selling at Oruka Therapeutics, Inc.

The buying activity by Agarwal stands out during a period when several other leaders at the company were trimming their holdings. On June 15, 2026, Chief Executive Officer Lawrence Otto Klein sold 1,729 shares at a price of $69.69, totaling about $120,494. On that same day, General Counsel Paul Quinlan sold 733 shares, and Chief Operating Officer Laura Lee Sandler sold 600 shares, both at the $69.69 price point. More recently, on October 15, 2026, Chief Medical Officer Joana Goncalves sold 7,000 shares at $74.81 each through a Rule 10b5-1 plan, a sale valued at approximately $523,647. Agarwal's own sale of 395 shares on June 15 was also a planned transaction.

Stock Price Trends and Market Position

Shares of Oruka Therapeutics are currently trading around $68.86 on Monday. The stock has shown plenty of movement over the past year, ranging from a low of $14.89 to a high of $115.52. While the current price is well above the 200-day moving average of $61.44, it has drifted back from the 50-day moving average of $96.41. The company carries a market value of roughly $6.18 billion and maintains a very high current ratio of 38.5, which suggests it has plenty of cash on hand to fund its ongoing clinical research.

Analysts Set New Price Targets

Financial analysts continue to view the company favorably. On September 24, 2026, Wedbush reiterated its outperform rating with a $165.00 price target, and HC Wainwright & Co. reaffirmed its buy rating with a $120.00 target. Guggenheim remains the most optimistic, sticking with a buy rating and a $200.00 price target as of August 11, 2026. Currently, the consensus among 12 analysts is a strong buy, with a collective average price target of $155.00, suggesting significant potential growth from recent levels.

Financial Results and Future Milestones

As a clinical-stage biotech company, Oruka is not yet profitable and does not have a meaningful P/E ratio. For the most recent period, the company reported a loss per share of $2.04 and a return on equity of -18.2%. Because it is focused on research and development, it did not generate revenue during this timeframe. Shareholders are looking toward November 11, 2026, when the company is scheduled to release its next financial update and likely provide progress reports on its drug pipeline.

About Oruka Therapeutics

Oruka Therapeutics is a Menlo Park-based biotechnology firm that develops treatments for chronic skin and inflammatory conditions. The company is primarily focused on monoclonal antibodies designed to treat psoriasis and psoriatic arthritis. Its lead candidates, including ORKA-001 and ORKA-002, are currently moving through Phase 2 clinical trials. These programs aim to provide more effective or longer-lasting options for patients suffering from immune-related disorders.

Future Outlook

The mixed insider activity, featuring both Agarwal's June purchase and subsequent sales by various executives, comes as the company approaches a critical earnings update in November. While the stock has retreated from its yearly highs, the strong cash position and high analyst price targets reflect a focus on the long-term success of its clinical trials. Investors will be watching the upcoming November 11 report for any new data from the ORKA-001 and ORKA-002 programs.